$CHRS
Coherus BioSciences Inc

2018 Q2 Form 10-Q Financial Statement

#000156459018020492 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q4 2017 Q2
Revenue $0.00 $0.00 $1.395M
YoY Change -100.0% -100.0% -90.08%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $18.39M $15.00M $23.50M
YoY Change -21.74% -1.96% 107.96%
% of Gross Profit
Research & Development $26.52M $31.50M $34.50M
YoY Change -23.13% -46.61% -47.36%
% of Gross Profit
Depreciation & Amortization $900.0K $900.0K $800.0K
YoY Change 12.5% 12.5% 14.29%
% of Gross Profit
Operating Expenses $44.91M $46.47M $58.03M
YoY Change -22.61% -37.47% -24.44%
Operating Profit -$44.91M
YoY Change
Interest Expense -$2.400M -$2.400M -$2.400M
YoY Change 0.0% 0.0% -201.95%
% of Operating Profit
Other Income/Expense, Net $3.600M -$200.0K $3.600M
YoY Change 0.0% 100.0% -171.15%
Pretax Income -$43.69M -$49.10M -$55.40M
YoY Change -21.15% -35.31% -21.08%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$43.64M -$49.07M -$55.34M
YoY Change -21.14% -35.37% -20.91%
Net Earnings / Revenue -3966.74%
Basic Earnings Per Share -$0.68
Diluted Earnings Per Share -$0.68 -$840.8K -$1.078M
COMMON SHARES
Basic Shares Outstanding 63.96M
Diluted Shares Outstanding 63.96M

Balance Sheet

Concept 2018 Q2 2017 Q4 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.8M $126.9M $118.3M
YoY Change 35.08% 1.6% -46.45%
Cash & Equivalents $130.0M $126.9M $73.35M
Short-Term Investments $29.80M $45.00M
Other Short-Term Assets $13.00M $142.0K $35.00M
YoY Change -62.86% -95.24% 8020.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $172.8M $145.5M $153.3M
YoY Change 12.72% -9.92% -35.27%
LONG-TERM ASSETS
Property, Plant & Equipment $11.20M $12.77M $14.50M
YoY Change -22.76% 18.27% 46.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $800.0K $800.0K
YoY Change 0.0% -57.42% 5233.33%
Total Long-Term Assets $15.50M $17.12M $19.00M
YoY Change -18.42% 0.81% 33.17%
TOTAL ASSETS
Total Short-Term Assets $172.8M $145.5M $153.3M
Total Long-Term Assets $15.50M $17.12M $19.00M
Total Assets $188.3M $162.6M $172.3M
YoY Change 9.29% -8.9% -31.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.30M $15.50M $15.80M
YoY Change -15.82% -21.34% -9.37%
Accrued Expenses $8.500M $6.976M $17.10M
YoY Change -50.29% -75.11% -10.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.20M $28.40M $35.95M
YoY Change -38.25% -49.65% -66.81%
LONG-TERM LIABILITIES
Long-Term Debt $102.3M $101.6M $100.9M
YoY Change 1.39% 1.3% 1.31%
Other Long-Term Liabilities $1.856M $2.073M $2.111M
YoY Change -12.08% -17.08% -97.99%
Total Long-Term Liabilities $1.856M $2.073M $2.111M
YoY Change -12.08% -97.98% -98.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.20M $28.40M $35.95M
Total Long-Term Liabilities $1.856M $2.073M $2.111M
Total Liabilities $126.5M $132.1M $141.4M
YoY Change -10.55% -16.41% -54.68%
SHAREHOLDERS EQUITY
Retained Earnings -$775.5M -$667.4M
YoY Change
Common Stock $927.1M $808.1M $700.2M
YoY Change 32.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.20M $30.54M $32.14M
YoY Change
Total Liabilities & Shareholders Equity $188.3M $162.6M $172.3M
YoY Change 9.32% -8.9% -31.4%

Cashflow Statement

Concept 2018 Q2 2017 Q4 2017 Q2
OPERATING ACTIVITIES
Net Income -$43.64M -$49.07M -$55.34M
YoY Change -21.14% -35.37% -20.91%
Depreciation, Depletion And Amortization $900.0K $900.0K $800.0K
YoY Change 12.5% 12.5% 14.29%
Cash From Operating Activities -$35.50M -$29.90M -$55.60M
YoY Change -36.15% -65.55% 102.92%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$100.0K -$1.000M
YoY Change -100.0% -97.22% 233.33%
Acquisitions
YoY Change
Other Investing Activities -$16.60M $14.50M $5.000M
YoY Change -432.0%
Cash From Investing Activities -$16.60M $14.40M $4.100M
YoY Change -504.88% -500.0% -1466.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 99.90M 6.900M -200.0K
YoY Change -50050.0% -87.68% -100.29%
NET CHANGE
Cash From Operating Activities -35.50M -29.90M -55.60M
Cash From Investing Activities -16.60M 14.40M 4.100M
Cash From Financing Activities 99.90M 6.900M -200.0K
Net Change In Cash 47.80M -8.600M -51.70M
YoY Change -192.46% -75.0% -224.88%
FREE CASH FLOW
Cash From Operating Activities -$35.50M -$29.90M -$55.60M
Capital Expenditures $0.00 -$100.0K -$1.000M
Free Cash Flow -$35.50M -$29.80M -$54.60M
YoY Change -34.98% -64.18% 101.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3290000
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
385000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
341000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22198000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28395000
CY2018Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
95000
CY2018Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
76750000
CY2018Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25583000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1856000
CY2018Q2 us-gaap Liabilities
Liabilities
126482000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
927129000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-537000
CY2018Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0
CY2018Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1395000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42869000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1702000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3130000
us-gaap Share Based Compensation
ShareBasedCompensation
16882000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-46000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1562000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-217000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69114000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13170000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29785000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47514000
chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsAndCommissions
100798000
chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsAndCommissions
124866000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
301000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
398000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
509000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
345000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
764000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101770000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
124813000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
213000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-43000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3084000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51595000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127756000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125792000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130840000
us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations<font style="font-weight:normal;"> </font></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the &#8220;Company&#8221;, &#8220;Coherus&#8221;, &#8220;we&#8221;, our&#8221; or &#8220;us&#8221;) is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital<font style="font-weight:normal;"> </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018, the Company had an accumulated deficit of $863.4 million and cash and cash equivalents and short-term investments in marketable securities of $159.8 million. In the first quarter of 2018, the Company issued and sold 192,642 shares of common stock at a weighted average price of $9.53 per share through its ATM Offering Program and received total net proceeds of $1.8 million. In April and May 2018, the Company issued and sold 1,451,137 shares of common stock at a weighted average price of $12.75 per share through its ATM Offering Program and received total net proceeds of $17.9 million. In May 2018, the Company completed an underwritten public offering of 5,948,274 shares of its common stock at a price to the public of $14.50 per share, which includes the closing of the full exercise of the underwriters&#8217; option to purchase an additional 775,861 shares of common stock. The Company received net proceeds from the offering of $80.8 million, after deducting the underwriting discounts and commissions and offering expenses (see Note 8). The Company believes that its current available cash and cash equivalents and short-term investments in marketable securities will be sufficient to fund its planned expenditures and meet the Company&#8217;s obligations <font style="color:#000000;">for at least 12 months following our financial statement issuance date</font><font style="color:#1F497D;">. </font>The Company will need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, clinical trial accruals, revenue recognition period, contingent consideration, convertible notes valuation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.&nbsp;&nbsp;</p></div>
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
159800000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73352000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
60000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
785000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18490771
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15216160
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2017Q2 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
158000
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
226000
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
204000
CY2017Q2 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
21000
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
40000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22796000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22575000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11626000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9802000
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
902000
CY2017Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
838000
CY2017Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
464000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
464000
CY2018Q2 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
2651000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5185000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
674000
CY2017Q2 us-gaap Restructuring Charges
RestructuringCharges
3600000
CY2018Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
2100000
CY2018Q1 us-gaap Restructuring Reserve
RestructuringReserve
0

Files In Submission

Name View Source Status
0001564590-18-020492-index-headers.html Edgar Link pending
0001564590-18-020492-index.html Edgar Link pending
0001564590-18-020492.txt Edgar Link pending
0001564590-18-020492-xbrl.zip Edgar Link pending
chrs-10q_20180630.htm Edgar Link pending
chrs-20180630.xml Edgar Link completed
chrs-20180630.xsd Edgar Link pending
chrs-20180630_cal.xml Edgar Link unprocessable
chrs-20180630_def.xml Edgar Link unprocessable
chrs-20180630_lab.xml Edgar Link unprocessable
chrs-20180630_pre.xml Edgar Link unprocessable
chrs-ex311_8.htm Edgar Link pending
chrs-ex312_7.htm Edgar Link pending
chrs-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending